SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Alper H.YUKSEL who wrote (15521)2/20/1998 4:05:00 PM
From: Hippieslayer  Read Replies (2) | Respond to of 32384
 
Good question, Alper. In regards to the NDA, what problems could the FDA bring up that would block the approval of Panretrin gel. Or is approval considered a "slam dunk" in light of the successful trials and the novel approach to treating KS?



To: Alper H.YUKSEL who wrote (15521)2/20/1998 4:05:00 PM
From: Henry Niman  Read Replies (2) | Respond to of 32384
 
Michael Murphy, on his hot line this week, predicted that LGND will got to the high teens or low 20's just before the NDA filing this quarter.



To: Alper H.YUKSEL who wrote (15521)2/20/1998 4:17:00 PM
From: Andreas Helke  Read Replies (2) | Respond to of 32384
 
I expect a strong up move in anticipation of the filing and I suspect that the recent rise from $11 to $15 was partially fueled by the anticipation of the NDA. What happens after the NDA filing depends on the price that Ligand has reached at the time of the filing. I think we have a chance to reach a new all time high. But I don't know if this happens before or after the filing. My 24 month price target stays at $30 to $50.

Andreas


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News